The United Kingdom and the United States have hammered out a landmark bilateral deal that will preserve no levies on UK pharmaceutical shipments entering the US market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has agreed to boost funding on drugs through the National Health Service (NHS). This commitment guarantees that import taxes on these vital goods will be held at zero for a timeframe of 36 months.
This deal comes after previous warnings to significantly raise tariffs on branded drug products, with figures floated as high as double the cost.
"This agreement between the United Kingdom strengthens the international landscape for innovative medicines and establishes much-needed equity to transatlantic pharmaceutical trade," a statement said.
Economic Impact
Medicines represent one of the the United Kingdom's most significant goods shipped to the United States, which is by far the largest destination for leading British pharmaceutical firms.
Statistics show that in the year to the end of last September, the UK shipped medicines totaling over eleven billion pounds to the US. This amount made up nearly one-fifth of total UK exports in that timeframe.
"This agreement protects jobs, increases capital expenditure and facilitates the UK to establish itself as a global hub for biotech and pharma," the Business and Trade Secretary remarked.
Key UK Commitments
The pact entails several specific pledges from the British government:
- Higher Cost Ceiling: The UK will raise the cost ceiling at which it deems new therapies to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a goal to raise overall NHS spending on drugs from 0.3 percent of the national economy to 0.6% over the coming ten years.
- Rebate Cap: The percentage pharmaceutical firms must pay back to the NHS to prevent overspending will be limited at fifteen percent. In the past, refunds exceeded 20%.
Recent Tensions
This agreement comes amid a protracted tension between the drug companies and the British authorities over drug pricing and NHS adoption.
The disagreement were intensified by arguments that US customers were paying several times more for the equivalent treatments than patients in the UK and Europe.
In recent months, several significant manufacturing plans in the UK have been delayed or abandoned, while major investments have been announced toward US facilities.
The Science Minister publicly accepted that the NHS must spend more on drugs, noting that its budget allocation on drugs had shrunk as a percentage of its overall budget over the previous ten-year period.
